Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

Kertzi Jun. 21 at 4:28 AM

Many pumper whiners complain that I don't own these shares. I doubled my $MTVA position at around $1.80, which was a huge mistake! I was looking for a quick payday since I never saw this as a long-term investment. Why? As a reminder, this "company" is an empty shell. All assets are owned by Korean Dong-ST. In the far future, if revenue is generated, what will the share be: 80% Dong and 20% MTVA? It only exists as an ATM for Dong-ST, and the money comes from shareholders.

0 · Reply

Basko151 Jun. 20 at 3:40 AM

$MTVA I just keep buying, buying, Buying…I had over 100k shares pre last reverse split and will have 50k for the next one…😕

0 · Reply

kgraphix Jun. 18 at 4:13 PM

$MTVA totally worthless ST discussion board here. Pretty much explains why it’s a POS ticket. Any thoughts about this stock? Anything? Anyone????

2 · Reply

kgraphix Jun. 13 at 9:23 PM

$MTVA so TF was that 5 min spike to .90 then back to red?? Anyone????

0 · Reply

Mr_Gambino Jun. 13 at 8:51 PM

$MTVA short above 1

0 · Reply

Go_Stock_yourself Jun. 13 at 1:21 AM

$MTVA https://youtu.be/mBWGPM_npNk?si=0hn-APjU2celxlHr

1 · Reply

kdnapedIPOmidweek Jun. 9 at 10:00 PM

$MTVA I think $ALT and $MTVA have a joint poster at the upcoming conference.

2 · Reply

BULLISH1975 Jun. 9 at 6:30 PM

$MTVA i hold this one for ages. thinking of buying back! if any of u are looking for another stock with 30 bagger potential this next year. check out $ICU!!! dyot

1 · Reply

kdnapedIPOmidweek Jun. 9 at 1:53 PM

$MTVA I’m in this because 48 percent of the float is owned by insiders … when she gets attention she is going to move fast

0 · Reply

Szepen Jun. 8 at 3:09 AM

$ALT $MTVA KOLs are working with several companies like Dr.Louis Aronne with Lilly and Altimmune paralell...it's just the way it is...

2 · Reply

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 16 days ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 5 weeks ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 6 weeks ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 6 weeks ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 2 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 2 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 2 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 3 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 5 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 7 months ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 7 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 8 months ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 8 months ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 9 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 9 months ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 10 months ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Jan 9, 2024, 8:30 AM EST - 1 year ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 2, 2024, 8:01 AM EST - 1 year ago

NeuroBo to Participate in Industry and Investor Conferences in January

Dec 28, 2023, 8:45 AM EST - 1 year ago

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Dec 19, 2023, 8:43 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 1, 2023, 8:31 AM EST - 1 year ago

NeuroBo to Participate in Investor Conferences in December

Nov 13, 2023, 4:05 PM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 8:05 AM EST - 1 year ago

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Oct 17, 2023, 8:01 AM EDT - 1 year ago

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sep 15, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Aug 14, 2023, 8:01 AM EDT - 2 years ago

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

Aug 9, 2023, 4:05 PM EDT - 2 years ago

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:01 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Kertzi Jun. 21 at 4:28 AM

0 · Reply

Basko151 Jun. 20 at 3:40 AM

$MTVA I just keep buying, buying, Buying…I had over 100k shares pre last reverse split and will have 50k for the next one…😕

0 · Reply

kgraphix Jun. 18 at 4:13 PM

$MTVA totally worthless ST discussion board here. Pretty much explains why it’s a POS ticket. Any thoughts about this stock? Anything? Anyone????

2 · Reply

kgraphix Jun. 13 at 9:23 PM

$MTVA so TF was that 5 min spike to .90 then back to red?? Anyone????

0 · Reply

Mr_Gambino Jun. 13 at 8:51 PM

$MTVA short above 1

0 · Reply

Go_Stock_yourself Jun. 13 at 1:21 AM

$MTVA https://youtu.be/mBWGPM_npNk?si=0hn-APjU2celxlHr

1 · Reply

kdnapedIPOmidweek Jun. 9 at 10:00 PM

$MTVA I think $ALT and $MTVA have a joint poster at the upcoming conference.

2 · Reply

BULLISH1975 Jun. 9 at 6:30 PM

$MTVA i hold this one for ages. thinking of buying back! if any of u are looking for another stock with 30 bagger potential this next year. check out $ICU!!! dyot

1 · Reply

kdnapedIPOmidweek Jun. 9 at 1:53 PM

$MTVA I’m in this because 48 percent of the float is owned by insiders … when she gets attention she is going to move fast

0 · Reply

Szepen Jun. 8 at 3:09 AM

$ALT $MTVA KOLs are working with several companies like Dr.Louis Aronne with Lilly and Altimmune paralell...it's just the way it is...

2 · Reply

BioRich Jun. 8 at 12:13 AM

$ALT I still think it's funny that while the ALT board was pumping how righteous Dr. Loomba was, he was actually presenting for the MASH capabilities of $MTVA at EASL. @Space_Dust, thoughts on this? Cheers!

3 · Reply

Love_To_Learn Jun. 6 at 10:47 AM

$MTVA yes 0.67 is me need to slightly shift u out of the way u out of positiion for now

0 · Reply

Ueberschlaefer Jun. 4 at 4:17 PM

$MTVA article says "new preclinical data." this is a major conference. however, conferences never pan out as expected if i own the stock. still, please baby jesus, let the have a great PR!

0 · Reply

prismmarketview Jun. 4 at 1:35 PM

$MTVA https://prismmarketview.com/metavia-to-present-preclinical-data-on-novel-gpr119-agonist-at-american-diabetes-association-conference/

0 · Reply

BioRich Jun. 4 at 2:49 AM

$ALT Can't wait for tomorrow's meltdown from $ALT Bulls followed by the excuses. I hope $AKRO, $MTVA, $ESPR and/or $VKTX drop news tomorrow. Would be a beautiful Humpday indeed! Cheers!

2 · Reply

Go_Stock_yourself Jun. 2 at 12:51 AM

$MTVA https://www.streetinsider.com/dr/news.php?id=24854505&gfv=1

0 · Reply

Go_Stock_yourself Jun. 1 at 5:12 PM

$MTVA knowing some warants expires in june and that the fda meeting is "supposedly" first half of 2025 . Maybe we have a chance this reaches 1$ ... But i'd bet another RS is coming our way .. for now im gonna stick to

2 · Reply

Go_Stock_yourself May. 30 at 9:18 PM

$MTVA "MetaVia Inc. receives Nasdaq non-compliance notice" https://ca.investing.com/news/sec-filings/metavia-inc-receives-nasdaq-noncompliance-notice-93CH-4043574

0 · Reply

Kertzi May. 30 at 1:57 PM

$MTVA FakePharma from Korea...

0 · Reply

Jw242 May. 29 at 7:41 PM

$MTVA outta here

2 · Reply

HolyShnikes May. 29 at 5:51 PM

$MTVA

0 · Reply

TraderRapp May. 28 at 3:57 AM

$MTVA another reverse split? Wow, they annihilated retails but also Dong-ST spending a bunch of $$ here too. Almost time to take another stab at this one.

2 · Reply

Market Cap	13.71M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	51,700
Avg Vol	869,624
Day's Range	N/A - N/A
Shares Out	19.59M
Stochastic %K	0%
Beta	0.18
Analysts	Strong Sell
Price Target	$14.33